Foscarnet—Ganciclovir Cytomegalovwus Retinitis Trial: 4. Visual Outcomes

Ophthalmology

Volumn 101, Issue 7, 1994, Pages 1250-1261

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

FOSCARNET; GANCICLOVIR;

ADOLESCENT; ADULT; AIDS RELATED COMPLEX; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEPHROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RETINA DETACHMENT; RETINITIS; THROMBOCYTOPENIA; VISUAL ACUITY; VISUAL FIELD;

EID: 0028066818     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-6420(94)31181-X     Document Type: Article

References (45)

1. Acquired immune deficiency syndrome. Ocular manifestations
2. Ophthalmic involvement in acquired immunodeficiency syndrome
3. A prospective study of the ophthalmologic findings in the acquired immune deficiency syndrome
4. Acquired immune deficiency syndrome. Pathogenic mechanisms of ocular disease
5. Retinal and gastrointestinal disease due to cytomegalovirus in patients with the acquired immune deficiency syndrome: prevalence, natural history, and response to ganciclovir therapy
6. Cytomegalovirus retinitis and acquired immunodeficiency syndrome
7. Ocular manifestations of acquired immune deficiency syndrome
8. Risk of developing cytomegalovirus retinitis in persons infected with the human immunodeficiency virus
9. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with Zdovudine. The Zidovudine Epidemiology Study Group
10. Correlation between CD4+ counts and prevalence of cytomegalovirus retinitis and human immunodeficiency virus-related noninfectious retinal vasculopathy in patients with acquired immunodeficiency syndrome
11. Treatment of serious cytomegalovirus infections with 9-(1,3-dihydroxy2-propoxymethyl) guanine in patients with AIDS and other immunodeficiencies
12. Treatment of cytomegalovirus retinopathy with ganciclovir
13. Treatment of cytomegalovirus retinitis with ganciclovir
14. Ganciclovir for the treatment and suppression of serious infections caused by cytomegalovirus
15. Cytomegalovirus retinitis and response to therapy with ganciclovir
16. Combined shortand long-term therapy for the treatment of cytomegalovirus retinitis using ganciclovir (BW B759U)
17. A controlled retrospective study of ganciclovir treatment for cytomegalovirus retinopathy. Use of a standardized system for the assessment of disease outcome
18. Longitudinal study of cytomegalovirus retinitis in acquired immune deficiency syndrome
19. Treatment of cytomegalovirus retinitis with trisodium phosphonoformate hexahydrate (foscarnet)
20. Foscarnet in the treatment of cytomegalovirus retinitis in acquired immune deficiency syndrome
21. Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome
22. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS
23. Studies of ocular complications of AIDS Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 1. Rationale, design, and methods
24. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis
25. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome
26. The use of nitrogen mustards in the palliative treatment of carcinoma: with particular reference to bronchogenic carcinoma
27. New visual acuity charts for clinical research
28. Photocoagulation treatment of proliferative diabetic retinopathy: the second report of Diabetic Retinopathy Study findings
29. The validity and reliability of photographic documentation of proliferative viteroretinopathy
30. Progression rates of cytomegalovirus retinopathy in ganciclovir-treated and untreated patients
31. Nonparametric estimation from incomplete observations
32. Asymptotically efficient rank invariant test procedures
33. Regression models and life-tables
34. Longitudinal data analysis for discrete and continuous outcomes
35. Pathologic features of cytomegalovirus retinopathy after treatment with the antiviral agent ganciclovir
36. Randomized prospective trial of ganciclovir maintenance therapy for cytomegalovirus retinitis
37. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type l
38. CD4 count and the risk for death in patients infected with HIV receiving antiretroviral therapy
39. Combinations of 3'-azido3'deoxythymidine (zidovudine) and phosphonoformate (foscarnet) against human immunodeficiency virus type 1 and cytomegalovirus replication in vitro
40. Synergistic inhibition of human immunodeficiency virus type 1 replication in vitro by two-drug and three-drug combinations of 3'-azido-3'-deoxythymidine, phosphonoformate, and 2',3'dideoxythymidine
41. In vivo additive antiretroviral effect of combined zidovudine and foscarnet therapy for human immunodeficiency virus infection (ACTG Protocol 053)
42. Visual dysfunction without retinitis in patients with acquired immunodeficiency syndrome
43. Morphometric comparisons of optic nerve axon loss in acquired immunodeficiency syndrome